Researchers investigated whether adjuvant therapy benefits patients with duodenal adenocarcinoma (DAC) and intestinal subtype ampullary carcinoma (IAC) after surgery. The study found that while DAC patients with perineural invasion and IAC patients with specific risk factors (lymph node involvement, advanced tumor stage, perineural invasion) benefited from adjuvant therapy, overall survival wasn’t improved in all cases. DAC and IAC shared some similarities, yet their responses to adjuvant treatment differed, highlighting the need for personalized approaches in managing these distinct cancers.
Journal Article by Finton S, Bolm L (…) Ferrone CR et 15 al. in Ann Surg
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.